key: cord-0294684-4uzzap6n
authors: Begin, P.; Callum, J.; Jamula, E. J.; Cook, R.; Heddle, N. M.; Tinmouth, A.; Zeller, M. P.; Beaudoin-Bussiere, G.; Amorim, L.; Bazin, R.; Cadogan Lofstgard, K.; Carl, R.; Chasse, M.; Cushing, M.; Daneman, N.; Devine, D. V.; Dumaresq, J.; Ferguson, D.; Gabe, C.; Glesby, M. J.; Li, N.; Liu, Y.; McGeer, A.; Robitaille, N.; Sachais, B. S.; Scales, D. C.; Schwartz, L.; Shehata, N.; Turgeon, A.; Wood, H.; Zarychanski, R.; Finzi, A.; Arnold, D. M.; Group, CONCOR-1 Study
title: Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
date: 2021-07-03
journal: nan
DOI: 10.1101/2021.06.29.21259427
sha: 7b1e0ea4bc7b84d182beb57b158541a4f30e2745
doc_id: 294684
cord_uid: 4uzzap6n

The efficacy of convalescent plasma for COVID-19 is unclear. While most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content may influence patient outcomes. We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 days of respiratory symptom onset. Patients were allocated 2:1 to 500 mL of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 days. The effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. 940 patients were randomized and 921 patients were included in the intent-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) in the convalescent plasma arm and 86/307 (28.0%) in the standard of care arm; relative risk (RR) 1.16 (95% confidence interval (CI) 0.94-1.43; p=0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% vs. 26.4%; RR=1.27, 95% CI 1.02-1.57, p=0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standard log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (OR=0.74; 0.57-0.95 and OR=0.66; 0.50-0.87, respectively), while IgG against the full transmembrane Spike protein increased it (OR=1.53, 95% CI 1.14-2.05). Convalescent plasma did not reduce the risk of intubation or death at 30 days among hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavourable antibody profiles may be associated with worse clinical outcomes compared to standard care.

The immune response after SARS-CoV-2 infection results in the formation of antibodies that can interfere with viral replication and infection of host cells in over 95% of patients. 1 Based on prior experience in other viral infections, 2 the use of convalescent plasma has been proposed as a therapeutic form of passive immunization for patients with acute Coronavirus Disease 2019 . 3, 4 Early in the pandemic, several small randomized trials found no difference in clinical outcomes. [5] [6] [7] [8] In the United States, an Extended Access Program outside of a controlled trial led to the use of convalescent plasma in over half a million patients. Data from these patients showed that the transfusion of plasma with high anti-SARS-CoV-2 antibody level was associated with a lower risk of death in non-intubated patients compared with lower antibody levels; however, this study lacked a control group. 9 The RECOVERY trial was a large randomized trial in 11, 558 hospitalized patients, which found the risk of death following administration of high-titer plasma was not different from standard of care. 10 The Convalescent Plasma for COVID-19 Respiratory Illness (CONCOR-1) trial was a multi-center, international, open-label, randomized controlled trial designed to assess the effectiveness and safety of COVID-19 convalescent plasma in hospitalized patients. The trial used plasma collected from four blood suppliers with a range of anti-SARS-CoV-2 antibody levels. The variability in antibody titers allowed for a characterization of the effect-modifying role of functional and quantitative antibodies on the primary outcome (intubation or death at 30 days).

CONCOR-1 was an investigator-initiated, multi-center, open-label, randomized controlled trial conducted at 72 hospital sites in Canada, the United States, and Brazil. 11 Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. Committee performed trial oversight and made recommendations following review of safety reports planned at every 100 patients and at the planned interim analysis based on the first 600 patients. External monitoring was performed at all sites to assess protocol adherence, reporting of adverse events, and accuracy of data entry. The full details of the study design, conduct, oversight, and analyses are provided in the protocol and statistical analysis plan, which are available online.

Eligible participants were >16 in Canada or >18 years of age in the United States and Brazil who were admitted to the hospital ward with confirmed COVID-19 and who required supplemental oxygen. The availability of ABO-compatible convalescent plasma from donors who had recovered from COVID-19 infection was an eligibility requirement. Exclusion criteria were: more than 12 days from the onset of respiratory symptoms, imminent or current intubation, a contraindication to plasma transfusion, or a plan for no active treatment. Consent was obtained from all donors and participants (or their legally authorized representative).

Patients were randomized in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer-generated, web-accessed randomization sequence (REDCap).

Randomization was stratified by site and age (<60 and ≥ 60 years) with allocation made with permuted blocks of size 3 or 6. Patients randomized to convalescent plasma received one or two units of apheresis plasma amounting to approximately 500 mL from one or two donors. The plasma was stored frozen and thawed as per standard blood bank procedures and infused within 24 hours of randomization. Patients were monitored by clinical staff for transfusion-related adverse events as per local procedures. Individuals assigned to standard of care received usual medical care as per routine practices at each site. The investigational product was prepared by Canadian Blood Services and Héma-Québec (Canada), New York Blood Center (USA), 12 and Hemorio (Brazil). Each supplier had different criteria for qualifying convalescent plasma units that were based on the presence of either viral neutralizing antibodies at a titer of >1:160 or antibodies against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein at a titer of >1:100. In addition, a sample from each plasma donation was tested at reference laboratories after the transfusion for: (1) anti-RBD antibodies (IgM, IgA and IgG) by enzyme-linked immunosorbent assay (ELISA); 13, 14 (2) viral neutralization by the plaque-reduction neutralization test using live virus; 15, 16 (3) IgG antibodies binding to the full-length trimeric transmembrane SARS-CoV-2 Spike protein expressed on 293T cells by flow cytometry; 17 and, (4) Fc-mediated function by an antibody-dependent cellular cytotoxicity (ADCC) assay against the full Spike protein expressed on CEM.NKr cells (see supplement for complete description). 18, 19 For each plasma unit, the absolute antibody content was defined as the product of the unit volume and the concentration of the antibody (or functional capacity) in the plasma. These calculations were used to estimate the total antibody content from the transfusion of two units.

The primary outcome was the composite of intubation or death by day 30. Secondary outcomes were: time to intubation or death; ventilator-free days by day 30; in-hospital death by day 90; time to in-hospital death; death by day 30; length of stay in critical care and hospital; need for extracorporeal membrane oxygenation; need for renal replacement therapy; convalescent plasmaassociated adverse events; occurrence of ≥3 grade adverse events by day 30 (classification of adverse events was performed using MedDRA (https://www.meddra.org/) and graded by the Common Terminology Criteria for Adverse Events, version 4.03). All transfusion-related adverse events were classified and graded by the International Society for Blood Transfusion definitions (www.isbtweb.org). All patients were followed to day 30, including a 30-day telephone visit for patients who were discharged from hospital. Patients who were in hospital beyond day 30 were followed until discharge for the purpose of determining in-hospital mortality up to day 90.

The primary analysis was based on the intention-to-treat population, which included all individuals who were randomized and for whom primary outcome data were available. The per-protocol population was comprised of eligible individuals who were treated according to the randomized allocation of the intervention and received two units (or equivalent) of convalescent plasma within 24 hours of randomization.

The effect of convalescent plasma on the composite primary outcome of intubation or death by day 30 was assessed by testing the null hypothesis that the composite event rate was the same under convalescent plasma and standard of care. The relative risk for the primary outcome (convalescent plasma versus standard of care) was computed with a 95% confidence interval. Secondary outcomes were analyzed as described in the statistical analysis plan (see supplementary material).

No multiplicity adjustments were implemented for the secondary analyses. Procedures planned for addressing missing data and subgroup analyses are described in the statistical analysis plan (see supplementary appendix). Forest plots were used to display point estimates and confidence intervals across subgroups with interaction tests used to assess effect modification.

The effect-modifying role of antibody content on the primary outcome was assessed via logistic regression controlling for the blood supplier, treatment, and the antibody marker. Antibody markers were log-transformed, centered and then divided by the corresponding standard deviation before being entered into logistic regression models (see statistical analysis plan, supplementary appendix). A multivariate logistic regression model was then fitted adjusting for all four markers.

Generalized additive models were used to examine the joint effect of each pair of serologic markers on the primary outcome. 20

The results from CONCOR-1 were subsequently included in a meta-analysis based on the May 20 th 2021 update of the Cochrane systematic review 8 and known randomised trials published since comparing convalescent plasma to placebo or standard care in patients with COVID-19. These were divided based on whether they used plasma with high antibody titre or not. For each trial, we compared the observed number of deaths at 30 days (or closest available time point prior to a crossover, if applicable) among patients allocated to convalescent plasma or the control group.

Summary estimates for relative risk with 95% confidence interval were calculated using randomeffects meta-analysis to account for variation in effect size amongst studies. Heterogeneity was quantified using inconsistency index (I 2 ) and p-values from the chi-square test for homogeneity.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint With a 2:1 randomization ratio, 1200 patients (800 in the convalescent plasma group, and 400 in the standard of care group) were needed to provide 80% power to detect a relative risk reduction of 25% with convalescent plasma for the primary outcome with a 30% event rate under standard of care, based on a two-sided test at the 5% significance level. An interim analysis by a biostatistician unblinded to the allocation of the intervention was planned for when the primary outcome was available for 50% of the target sample. An O'Brien-Fleming stopping rule was employed 21 to control the overall type-I error rate at 5%. Conditional power was used to guide futility decisions with the nominal threshold of 20% to justify early stopping.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021.

The trial was stopped at the planned interim analysis because the conditional power estimate was 1.6% (below the stopping criterion of 20%). Between May 14 th 2020 and January 29 th 2021, 940 patients were randomized (Figure 1 , eTable 1). Seventeen patients were lost to follow up between discharge and day 30 and two withdrew consent. Baseline demographics were balanced between groups for all study populations (Tables 1, eTable 2, 3). Median age was 69 years, with 59% male and the median time from the onset of any COVID-19 symptom was 8 days (interquartile range, 5

to 10). The majority of participants (84.0%) were receiving systemic corticosteroids at the time of enrolment.

In the intention-to-treat population (n=921), intubation or death occurred in 199 (32.4%) of 614 patients in the convalescent plasma group and 86 (28.0%) of 307 in the standard of care group [relative risk (RR) 1.16; 95% confidence interval (CI) 0.94 to 1.43; p=0.18] ( Table 2) . The time to intubation or death was not significantly different between groups (eFigure 2). In the per-protocol analysis (n=851), intubation or death occurred in 167 (30.5%) of 548 patients in the convalescent plasma group and 85 (28.1%) of 303 patients in the standard of care group (RR=1.09; 95% CI 0.87 to 1.35; p=0.46) (eTable 4).

Secondary outcomes for the intention-to-treat population are provided in Table 2 . There were no differences in mortality or intubation or other secondary efficacy outcomes. Similarly, in the perprotocol analysis there were no differences in the secondary efficacy outcomes (eTable 4). No significant differences were observed in any of the pre-specified subgroups for both the intentionto-treat ( Figure 2 ) and per-protocol populations (eFigure 1).

Serious adverse events occurred in 205 (33.4%) of 614 patients in the convalescent plasma arm compared to 81 (26.4%) of 307 patients in the standard of care arm for the intention-to-treat population (RR=1.27, 95% CI 1.02 to 1.57, p=0.034; eTable 5). Most of these events were worsening hypoxemia and respiratory failure. Transfusion related complications were recorded in 35 (5.7%) of 614 patients in the convalescent plasma group (eTable 7). Of the 35 reactions, 4 were life-threatening (2 transfusion-associated circulatory overload, 1 possible transfusion-related acute lung injury, 1 transfusion-associated dyspnea), and none were fatal. Thirteen of the 35 reactions were classified as transfusion-associated dyspnea. Two patients underwent serological investigation for transfusion-related acute lung injury (both negative).

The distributions of antibodies in convalescent plasma units varied by blood supplier (Figure 3, eTable 9); therefore, antibody analyses controlled for supplier to address possible confounding.

Transfusion of convalescent plasma with average (log-transformed) levels of ADCC yielded an odds ratio of 1.16 (95% CI: 0.85, 1.57) for the primary outcome relative to standard of care. Each one unit increase in the standardized log transformed ADCC was associated with a 24% reduction in the odds ratio of the treatment effect (OR = 0.76, 95% CI: 0.62-0.92) (Figure 3 , eTable 10). This effect modifying role was also significant for the neutralization test (OR=0.77; 0.63-0.94), but not for anti-RBD ELISA (OR=0.84; 0.69-1.03), or IgG against the full transmembrane Spike (OR=1.01; 0.82-1.23).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. ;  When all four serologic markers were included in the multivariate model, each one unit increase in the standardized log transformed anti-Spike IgG marker was associated with a 53% increase in the odds ratio for the deleterious effect of convalescent plasma on the primary outcome (OR=1.53, 95% CI 1.14-2.05); increases in ADCC and neutralization independently improved the effect of CCP (OR=0.66; 0.50-0.87 and OR=0.74; 0.57-0.95, respectively) while levels of anti-RBD antibodies had no effect-modifying role (OR=1.02; 0.76, 1.38) (eTable 10). There was no evidence of significant interaction between the four serologic measures in the general additive model ( Figure   3 , eTable 10).

Of the fifteen other reported randomised trials, eleven used only high-titre plasma 5, 7, 22-30 and four applied less stringent plasma selection criteria allowing for variable plasma titres 6, 31-33 . Including the results from CONCOR-1, a total of 15,301 patients were included in the trials using high-titre plasma and 968 participated in a trial applying less stringent criteria. The summary estimates for the relative risk of mortality in high-titre plasma trials was 0.97 (95% CI 0.92 -1.02), compared to 1.25 (95% CI 0.92-1.69) in trials using unselected convalescent plasma (Figure 4 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint

The CONCOR-1 trial found that the use of convalescent plasma for the treatment of hospitalized patients with COVID-19 did not reduce the risk of intubation or death at 30 days. Patients in the convalescent plasma arm experienced more serious adverse events. Convalescent plasma was not associated with an improvement in any of the secondary efficacy outcomes or in any of the subgroups. These results are consistent with the RECOVERY trial and a recent Cochrane metaanalysis. 8, 10 A major additional contribution of our study comes from the study of immunologic markers, which suggest that the antibody profile significantly modified the effect of convalescent plasma compared to standard of care.

The RECOVERY trial showed that transfusion of high-titer plasma was no better than standard of care in prevention of key outcomes. 10 The US National Registry report showed that high antibody level plasma was associated with a 34% relative risk reduction in mortality compared to low antibody level plasma. 9 Our assessment of the role of antibody profile on the clinical effect relative to standard of care is aligned with both of these conclusions. In the RECOVERY trial, plasma with a commercial ELISA cut-off corresponding to a neutralizing antibody titer of 100 or greater was used and the mortality rate ratio compared with standard of care was 1.00 (95% CI 0.93-1.07). 10 In our trial, plasma from one of the blood suppliers (blood supplier 1) that used a similar antibody threshold (neutralizing antibody titer of 160 of greater) was associated with a similar effect size [OR 0.95 (95% CI 0.73-1.25)] ( Figure 3 ). In contrast, the US National Registry study, which lacked a control group, reported that plasma containing high antibody levels (Ortho Vitros IgG anti-Spike subunit 1, which contains the receptor binding domain (RBD), signal to cut-off ratio > 18.45) was associated with a 34% reduction in mortality compared to plasma containing low antibody levels (signal to cut-off ratio < 4.62). 9 In our regression model (eTable 10), plasma with anti-RBD ELISA values corresponding to this low antibody cut-off ( Figure 3 ) would have a predicted OR of 1.49 compared with controls (95% CI: 0.98-2.29), while plasma with the corresponding high antibody cut-off would have a predicted OR of 0.91 (95% CI: 0.60-1.40), representing a 38% relative risk reduction. Thus, the 34% relative risk reduction observed by US National Registry 9 could be explained by increased mortality with low antibody plasma, rather than improved mortality with high antibody plasma. This conclusion is corroborated by the meta-analysis of previous trials based on plasma selection strategy. While the vast majority of patients included in convalescent plasma trials received with high-titre plasma, most patients treated outside of clinical trials did not, including many of those who received plasma by the current FDA requirements (Ortho Vitros ≥ 9.5). Only 20% of convalescent plasma included in the US National registry was considered high-titre 9 . In our study blood supplier 3 used the same plasma as the one used in clinic as part of the EUA, and in our subgroup analysis convalescent plasma from this blood supplier was associated with worse clinical outcomes (OR=1.89, 95%CI 1.05 -3.43).

The antibody content is critical in determining the potency and potential harm of passive antibody therapy. Convalescent plasma demonstrating high levels of viral neutralization and high levels of Fc-mediated function were independently associated with a reduced risk for intubation or death.

The importance of Fc-mediated function is in line with the known functional determinants of the anti-SARS-CoV-2 humoral response. In animal models of COVID-19, mutation of monoclonal antibodies leading to loss of Fc-mediated function, but sparing the neutralizing function, abrogated the protective effect of the antibody. [34] [35] [36] [37] In cohort studies of severe COVID-19, low Fc-mediated function but not neutralization was associated with mortality. 38, 39

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. ;  In contrast, high levels of IgG antibodies against the full transmembrane Spike protein measured by flow cytometry (which are distinct from commercial assays for IgG against Spike subunit 1) were associated with an increased risk of intubation or death after controlling for other antibody markers, suggesting that the transfusion of convalescent plasma containing non-functional anti-SARS-CoV-2 antibodies may be harmful. Antibody Fc-mediated function is dependent on the ability to aggregate and crosslink Fc receptors on target cells. This process can be disrupted by competition One positive clinical trial in mild disease (n=160) found that high-titer convalescent plasma administered within 72 hours of the onset of mild COVID-19 symptoms improved clinical outcomes compared with placebo in an elderly outpatient population. 25 Furthermore, in a Bayesian re-analysis of the RECOVERY trial, the subgroup of patients who had not yet developed anti-SARS-CoV-2 antibodies appeared to benefit from convalescent plasma. 44 The C3PO trial, which also assessed early treatment with high-titer plasma in high-risk patients, was stopped prematurely for futility after enrolling 511 of 900 planned participants (NCT04355767). In our trial, the median time from the onset of symptoms was 8 days; however, we did not observe a difference in the primary outcome in the subgroup of patients who received convalescent plasma within three days from diagnosis.

The frequency of serious adverse events was higher in the convalescent plasma group compared with the standard of care group (33.4% vs. 26.4%; RR=1.27, 95% CI 1.02-1.57). Most of these events were caused by worsening hypoxemia and respiratory failure occurring throughout the 30 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021.

day follow up period. This frequency is consistent with the recent Cochrane review which reported an OR of 1.24 (95% CI 0.81-1.90) for serious adverse events. 8 The frequency of transfusionassociated dyspnea and transfusion-associated circulatory overload were 2.1% and 0.8%, respectively, similar to other studies of non-convalescent plasma. 45 The rates of transfusion reactions in CONCOR-1 were higher than what was reported in the RECOVERY trial, where transfusion reactions were reported in 13 (0.22%) of 5795 patients. 10 CONCOR-1 site investigators included many transfusion medicine specialists and the open-label design may have encouraged reporting. However, the rate of serious transfusion-related AEs was low (4 of 614 (0.65%) convalescent plasma treated patients) and thus, does not explain the difference in serious adverse events between groups.

CONCOR-1 was a novel randomized trial designed to examine the effect of convalescent plasma versus standard of care for the primary composite outcome of intubation of death, with a capacity to explore the immunological profile of convalescent plasma and its impact on the effect of convalescent plasma. The trial involved four blood suppliers that provided local convalescent plasma units based on different antibody criteria. As a result, plasma units with a wide distribution of antibody content were included, and comprehensive antibody testing using both quantitative and functional assays provided a detailed description of the plasma product. The open-label design represents a limitation of this study as knowledge of the treatment group could influence the decision to intubate, report adverse events, or administer other treatments. The antibody profile of the recipient was unavailable at the time of this analysis. In future work we will investigate the value of convalescent plasma in patients without a detectable humoral immune response. In addition, other antibody isotypes (IgM and IgA) and IgG subclasses should be evaluated in future studies to determine their effect on clinical outcomes.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint

In summary, the CONCOR-1 trial did not demonstrate a difference in the frequency of intubation or death at 30 days with convalescent plasma or standard of care in hospitalized patients with COVID-19 respiratory illness. The antibody content had a significant effect-modifying role for the impact of convalescent plasma on the primary outcome. The lack of benefit and the potential concern of harm cautions against the unrestricted use of convalescent plasma for hospitalized patients with COVID-19.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint receive payments from any pharmaceutical company or other agency to write this article. All the authors had full access to the full data in the study and accept responsibility to submit for publication. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. 

De-identified individual patient data with the data dictionary that underlie the reported results will be made available upon request if approved by the CONCOR-1 Steering Committee. Proposals for access should be sent to arnold@mcmaster.ca. The protocol and statistical analysis plan are available online.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint Tables   Table 1: Characteristics of the study population at baseline (excluding two patients who withdrew consent). Categorical data presented as number (percentage) and continuous variables as mean ± standard deviation and median (interquartile range). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint a Relative Risk (RR, 95% confidence interval), Hazard Ratio (HR, 95% confidence interval) and Mean Difference (MD, with 95% CI based on robust bootstrap standard errors) b 17 patients discharged before day 30 and lost to follow-up at 30 days, and 2 withdrew consent before day 30, thus outcomes collected at day 30 (primary outcome and some other secondary outcomes for day 30) were missing. c Excluding 11 patients on chronic kidney replacement therapy at baseline d Excluding 2 patients that withdrew consent prior to outcome . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Per protocol analysis Intention to treat analysis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint Panel A presents boxplots of absolute antibody amounts transfused to the patients in the convalescent plasma (CCP) arm for each of the serologic marker, expressed as the product of their concentration measure and the volume. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers. Panel B presents the effect-modifying role of CCP antibody content for the primary outcome for each antibody measure taken individually. The top row presents the plots of the trends in the convalescent plasma effect compared to standard of care (SOC) as a function of the marker value, along with 95% confidence intervals, obtained from generalized additive models for each marker taken individually. Marker values are expressed as standard deviations of log values centered around the mean (standardized log). The horizontal dotted line represents a convalescent plasma with no effect (OR=1). The p-values imbedded in the plots (test for trend) refer to the effect modification observed with each increase of one standardized log of the marker (see table S10). The histograms in the second row present the frequency distribution of observed marker values. Panel C gives the contour plots of the odds ratio for the odds ratio for the composite event of intubation or death for individuals receiving blood as a function of the antibody-dependent cellular cytotoxicity (ADCC) ratio and the neutralization titer. Over-layed data points indicate the value of the two antibody markers for each convalescent plasma transfusion in the study, with color code indicating blood supplier. The contours are obtained from a generalized additive logistic model for the primary outcome including blood supply center, treatment and the log transformed and standardized biomarkers using smoothing splines. Panel D similarly explores the joint effect of the ADCC ratio and levels of IgG against the SARS-CoV-2 full transmembrane Spike protein on the primary outcome. ADCC: Antibody-dependent cellular cytotoxicity; CCP: COVID-19 convalescent plasma; IgG: immunoglobulin G; OR: odds ratio; RBD: receptor-binding domain; S: SARS-CoV-2 Spike protein; SOC: standard of care.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. 

Favours unselected CCP Favours Control RR (95% CI)

Panel A present the meta-analysis including trials that used high-titer plasma, whereas panel B presents those in which plasma which used a mix of low, medium and high-titre plasma. CCP: Covid-19 convalescent plasma; RR: relative risk.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. 

An AE is any untoward medical occurrence that occurs in a patient or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with the treatment assignment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product.

An ADR is any noxious and unintended response to an IMP related to any dose. The phrase 'response to an IMP' means that a causal relationship between the IMP and an AE carries at least a reasonable possibility, i.e., the relationship cannot be ruled out.

Any marked laboratory abnormalities or any AEs that lead to an intervention, including withdrawal of drug treatment, dose reduction, or significant additional concomitant therapy.

The severity of each AE must be assessed by the Investigator and graded based on CTCAE v4.03. A clinical AE NOT identified elsewhere in the grading table will be graded using one of the following categories: 

A SAE is generally defined as any untoward medical occurrence that at any dose:

2. Is life-threatening; this means that the subject is at risk of death at the time of the event; it does not mean that the event hypothetically might have caused death if it was more severe;

3. Requires hospitalization (overnight or longer) or prolongation of existing hospitalization or invasive procedure; 4. Results in persistent or significant disability or incapacity; 5. Results in congenital anomaly or birth defect; 6. Is not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or require intervention to prevent one of the above outcomes.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint 9

The primary outcome is a composite of intubation or death at Day 30. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint

Study data were collected and managed using REDCap electronic data capture tools hosted at McMaster University. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021.

Recombinant SARS-CoV-2 S RBD proteins (2.5 μg/ml), were prepared in PBS and were adsorbed to plates (100 µl/well; Immulon 2HB, Thermo Scientific ) overnight at 4°C. Coated wells were subsequently blocked with blocking buffer (Phosphate-buffered saline [PBS] containing 0.1% Tween20 and 2% BSA) for 1h at room temperature. Wells were then washed four times with washing buffer (PBS containing 0.1% Tween20). CR3022 mAb (50ng/ml final concentration) or plasma from SARS-CoV-2-infected or uninfected donors (1/100 dilution )in blocking buffer) were incubated with the RBD-coated wells for 1h at room temperature. Plates were washed four times with washing buffer followed by incubation with HRP conjugated goat anti-human IgA+IgG+IgM diluted in blocking buffer (Jackson ImmunoResearch Laboratories, Inc.) for 1h at room temperature, followed by four washes. HRP enzyme activity was determined after a 20 minute incubation with 3,3',5,5'-Tetramethylbenzidine (TMB, ESBE Scientific) followed by blocking with H2SO4 1N. Plates were read using a microplate reader (Synergy H1, Bio-Tek) within 30 min after blocking the reaction. The cutoff value for seropositivity, set at 0.250, was calculated using the mean OD + 3 standard deviations of 13 COVID-19 negative plasma samples (collected in 2019, before the outbreak of SARS-CoV-2) plus a 15% inter-assay coefficient of variation. Following implementation of the assay, we used results from the analysis of 94 convalescent plasma samples and 88 negative samples and the determined cut-off value yielded a sensitivity of 98.9% and a specificity of 98.5%.

293T and 293T.SARS-CoV-2.Spike cells 2 were mixed at a 1:1 ratio and stained with the anti-RBD monoclonal antibody CR3022 (5 µg/mL) or plasma (1/250 dilution) for 45 minutes at 37°C. Cells were then washed 2 times with PBS before being incubated with secondary antibodies. AlexaFluor-647 conjugated goat anti-human IgA, IgM, IgM+IgG+IgA (1,70 µg/mL; Jackson ImmunoResearch) or AlexaFluor-647 conjugated mouse anti-human IgG (3 µg/mL; Biolegend) were used as secondary antibodies to stain cells for 20 minutes at room temperature. Cells were then washed 2 times with PBS before being fixed in 2 % PBS-formaldehyde solution. The percentage of transduced cells (GFP+ cells) was determined by gating on the living cell population based on viability dye staining (AquaVivid, Thermo Fisher Scientific). Samples were acquired on a LSRII cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.7.1 (Tree Star).

ADCC was measured as described previously. 3 Briefly, parental CEM.NKr CCR5+ cells were mixed at a 1:1 ratio with CEM.NKr.SARS-CoV-2.Spike cells. These cells were stained for viability (AquaVivid; Thermo Fisher Scientific) and cellular dye (cell proliferation dye eFluor670; Thermo Fisher Scientific) to be used as target cells. Overnight rested PBMCs from healthy donors were stained with another cellular marker (cell proliferation dye eFluor450; Thermo Fisher Scientific) and used as effector cells. Stained target and effector cells were mixed at a ratio of 1:10 in 96-well V-bottom plates. Plasma (1/500 dilution) or monoclonal antibodies CR3022 and CV3-13 (1 µg/mL) were added to the appropriate wells. 4 The plates were subsequently centrifuged for 1 min at 300xg, and incubated at 37°C, 5% CO2 for 5 hours before being fixed in a 2% PBS-formaldehyde solution. ADCC activity (ADCC%) was calculated using the formula: Targets) x 100 by gating on transduced live target cells. Plasma from previous experiments and two monoclonal antibodies (CR3022, CV3-13) were used as quality controls and to standardize the ADCC ratio between experiments. All samples were acquired on an LSRII cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.7.1 (Tree Star).

The PRNT assay at NML was performed as previously published. 5 SARS-CoV-2 (Canada/ON_ON-VIDO-01-2/2020, EPI_ISL_42517) stocks were titrated for use in the PRNT. Serological specimens were diluted 2-fold from 1:20 to 1:640 in DMEM supplemented with 2% FBS and incubated with 50 PFU of SARS-CoV-2 at 37°C and 5% CO2 for 1 hour. The sera-virus mixtures were added to 12-well plates containing Vero E6 cells at 100% confluence, followed by incubation at 37°C and 5% CO2 for 1 hour. After adsorption, a liquid overlay composed of 1.5% carboxymethylcellulose 12 diluted in MEM, supplemented with 4% FBS, L-glutamine, nonessential amino acids, and sodium bicarbonate, was added to each well; the plates were incubated at 37°C and 5% CO2 for 72 hours. The liquid overlay was removed, and the cells were fixed with 10% neutral-buffered formalin for 1 hour at room temperature. The monolayers were stained with 0.5% crystal violet for 10 minutes and washed with 20% ethanol. Plaques were enumerated and compared with controls. The highest serum dilution resulting in 50% and 90% reduction in plaques compared with controls were defined as the PRNT50 and PRNT90 endpoint titers, respectively.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint 14 eTable 2: Baseline characteristics of the intention to treat population.

Excluding the 19 patients lost to follow-up at day 30 or withdrawing consent before day 30. Categorical data presented as number (percentage) and continuous variables as mean ± standard deviation and median (interquartile range). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint eTable 3: Baseline characteristics of the per protocol population.

Categorical data presented as number (percentage) and continuous variables as mean ± standard deviation and median (interquartile range). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. Figure 1 for exclusions to the per protocol population c Excluding 9 patients on chronic kidney replacement therapy at baseline d Including 15 additional patients above the per-protocol, n=851, who were lost to follow-up after discharge from hospital . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. Adverse event classified by the investigator as CTCAE term "death (not otherwise specified)".

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint 24 eTable 7: Adverse events at day 30 for the per protocol population.

Categorical data presented as number (percentage) and continuous variables as mean ± standard deviation and median (interquartile range). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. Adverse event classified by the investigator as CTCAE term "death (not otherwise specified)".

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint 30 eTable 10: Summary of logistic regression models with standardized continuous log marker dose.

The odds ratio reported in the third column reflects the effect modification corresponding to a 1 standard deviation unit increase in the log transformed and entered marker; in multivariate results markers other than the one labeled in the left column are set to mean log marker dose so the other covariates are zero. The convalescent plasma units transfused in the trial came from 530 distinct plasma donations. Five were missing all serologic marker values except for the original qualifying test and were excluded from analyses. Seven were missing only the neutralization titer value, which was interpolated from the other serologic markers, as described in the statistical analysis plan. Anti-RBD ELISA 1·018 (0·753, 1·376), p=0·9076

Anti-S IgG 1·528 (1·140, 2·049), p=0·0046

Neutralization 0·735 (0·567, 0·953), p=0·0200

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint eFigure 2: Cumulative incidence functions of intubation or in-hospital death by day 30 and in-hospital death by day 90, and Kaplan-Meier estimate of distribution of length of stay in hospital by day 90. Figure S2a : Cumulative incidence function for intubation or in-hospital death by day 30. Figure S2b : Cumulative incidence function for in-hospital death or discharge from hospital by day 90. Values from the Héma-Québec in-house ELISA measuring antibody (IgM, IgA, IgG) binding the receptor binding domain of SARS-CoV-2 Spike protein (used in the current study) are compared to results from A) Euroimmun and B) Ortho Vitros commercial assays measuring IgG binding to subunit 1 of the SARS-CoV-2 Spike protein, which contains the receptor binding domain and which were used to qualify convalescent plasma in previous clinical trials. Each sample was tested with the commercial assays twice.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 3, 2021. ; https://doi.org/10.1101/2021.06.29.21259427 doi: medRxiv preprint

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol

Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis

How should we use convalescent plasma therapies for the management of COVID-19? Blood

Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network. Transfusion

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood

A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight

Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2

Principal Investigator)

Laveena Munshi, Samia Saeed, Omar Hajjaj, Elaine Hsu, and the Medical Laboratory Technologists at Mount Sinai Hospital Niagara Health System

Eneko Arhanchiague (Principal Investigator)

Shuoyan Ning (Principal Investigator)

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset

Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects

A simple protein-based surrogate neutralization assay for SARS-CoV-2